Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGT2B7 | P16662 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isolongifolol SCHEMBL10784534 | 1.00 | UGT2B7 (1.00) | UGT2B7 | |
| Isolongifolol SCHEMBL29511507 | 1.00 | UGT2B7 (1.00) | UGT2B7 | |
| Isolongifolol SCHEMBL6514140 | 1.00 | UGT2B7 (1.00) | UGT2B7 | |
| Isolongifolol SCHEMBL29638247 | 1.00 | UGT2B7 (1.00) | UGT2B7 | |
| SCHEMBL7164598 | 0.82 | UGT2B7 (0.70) | UGT2B7 | |
| SCHEMBL11191517 | 0.78 | UGT2B7 (0.63) | UGT2B7 | |
| SCHEMBL3116086 | 0.75 | UGT2B7 (0.60) | UGT2B7 | |
| SCHEMBL2992626 | 0.74 | UGT2B7 (0.58) | UGT2B7 | |
| Isolongifolic Acid SCHEMBL29865033 | 0.72 | UGT2B7 (1.00) | UGT2B7 | |
| SCHEMBL3001348 | 0.71 | UGT2B7 (0.64) | UGT2B7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022217147-A1 | METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES | ROSENFELD MARK J (US) | 2022-10-13 | — | — | WO | claimed |
| US-20250195409-A1 | METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES | Ananda Scientific, Inc. (US) | 2025-06-19 | — | — | US | disclosed |
| CN-114668824-B | Application of alpinia zerumbet essential oil | 昆明理工大学 | 2023-08-01 | — | — | CN | disclosed |
| WO-2022217147-A1 | METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES | ROSENFELD MARK J (US) | 2022-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250195409-A1 | METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES | CNR2, CNR1, FAAH | UGT2B7 868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.